RALGPS1

Summary

RALGPS1 (Ral GEF with PH domain and SH3 binding motif 1, HGNC:16851) is a protein-coding gene on chromosome 9q33.3, encoding Ras-specific guanine nucleotide-releasing factor RalGPS1 (Q5JS13). Guanine nucleotide exchange factor (GEF) for the small GTPase RALA.

Enables guanyl-nucleotide exchange factor activity. Involved in regulation of Ral protein signal transduction. Predicted to be located in cytoplasm. Predicted to be active in plasma membrane.

Source: NCBI Gene 9649 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 54 total
• MANE Select transcript: NM_014636

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16851
Approved symbol	RALGPS1
Name	Ral GEF with PH domain and SH3 binding motif 1
Location	9q33.3
Locus type	gene with protein product
Status	Approved
Aliases	RALGPS1A, RALGEF2, KIAA0351
Ensembl gene	ENSG00000136828
Ensembl biotype	protein_coding
OMIM	614444
Entrez	9649

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 16 protein_coding, 5 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000259351, ENST00000319107, ENST00000373434, ENST00000373436, ENST00000373439, ENST00000394011, ENST00000394022, ENST00000424082, ENST00000438723, ENST00000467325, ENST00000471643, ENST00000472427, ENST00000477700, ENST00000480993, ENST00000903174, ENST00000903175, ENST00000903176, ENST00000921398, ENST00000921399, ENST00000921400, ENST00000921401, ENST00000968097

RefSeq mRNA: 13 — MANE Select: NM_014636 NM_001190728, NM_001190729, NM_001190730, NM_001322320, NM_001322321, NM_001322322, NM_001322323, NM_001322324, NM_001322325, NM_001366399, NM_001366400, NM_001366401, NM_014636

CCDS: CCDS35143, CCDS55344, CCDS55345, CCDS55346, CCDS94484

Canonical transcript exons

ENST00000259351 — 19 exons

Exon	Start	End
ENSE00000806793	127196474	127196631
ENSE00000806794	127199015	127199066
ENSE00001399772	126914782	126914975
ENSE00001615084	127174715	127174782
ENSE00001642587	127218740	127223166
ENSE00001705184	127168679	127168772
ENSE00001758580	127166069	127166206
ENSE00001782812	127195091	127195217
ENSE00003467780	127034431	127034514
ENSE00003478854	127052847	127052939
ENSE00003529241	127212131	127212236
ENSE00003548747	127212944	127213049
ENSE00003550853	127212627	127212719
ENSE00003617599	126965844	126965951
ENSE00003618467	127214751	127214842
ENSE00003620578	126977695	126977745
ENSE00003628748	127050043	127050132
ENSE00003651353	126962225	126962346
ENSE00003660119	127069230	127069356

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 96.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.8756 / max 217.5538, expressed in 1287 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
98580	6.5606	1283
98582	0.1984	119
98581	0.1167	65

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	96.79	gold quality
jejunal mucosa	UBERON:0000399	93.19	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.77	gold quality
cerebellar cortex	UBERON:0002129	92.15	gold quality
cerebellar hemisphere	UBERON:0002245	92.13	gold quality
cerebellum	UBERON:0002037	91.73	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.71	gold quality
spinal cord	UBERON:0002240	90.42	gold quality
duodenum	UBERON:0002114	90.30	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.29	gold quality
cerebellar vermis	UBERON:0004720	90.25	gold quality
endothelial cell	CL:0000115	89.71	gold quality
primary visual cortex	UBERON:0002436	89.69	gold quality
ganglionic eminence	UBERON:0004023	89.59	gold quality
middle temporal gyrus	UBERON:0002771	89.57	gold quality
apex of heart	UBERON:0002098	88.57	gold quality
prefrontal cortex	UBERON:0000451	87.94	gold quality
occipital lobe	UBERON:0002021	87.85	gold quality
small intestine	UBERON:0002108	87.83	gold quality
right uterine tube	UBERON:0001302	87.73	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.66	gold quality
right frontal lobe	UBERON:0002810	87.59	gold quality
neocortex	UBERON:0001950	87.29	gold quality
frontal cortex	UBERON:0001870	87.28	gold quality
postcentral gyrus	UBERON:0002581	87.22	gold quality
pituitary gland	UBERON:0000007	87.20	gold quality
Brodmann (1909) area 9	UBERON:0013540	87.01	gold quality
corpus callosum	UBERON:0002336	86.87	gold quality
cerebral cortex	UBERON:0000956	86.85	gold quality
central nervous system	UBERON:0001017	86.82	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.97

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IRX1

miRNA regulators (miRDB)

251 targeting RALGPS1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580

Literature-anchored findings (GeneRIF, showing 2)

• The guanine-nucleotide exchange factor (GEF) RalGPS1a activates small GTPase Ral proteins such as RalA and RalB by stimulating the exchange of Ral bound GDP to GTP, thus regulating various downstream cellular processes. (PMID:21494904)
• Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma. (PMID:34745385)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ralgps1	ENSDARG00000068370
mus_musculus	Ralgps1	ENSMUSG00000038831
rattus_norvegicus	Ralgps1	ENSRNOG00000016910

Paralogs (24): RASGRF1 (ENSG00000058335), RASGRP2 (ENSG00000068831), RAPGEF3 (ENSG00000079337), RAPGEF4 (ENSG00000091428), SOS2 (ENSG00000100485), RAPGEF1 (ENSG00000107263), RAPGEFL1 (ENSG00000108352), RAPGEF2 (ENSG00000109756), RASGRF2 (ENSG00000113319), SOS1 (ENSG00000115904), RALGPS2 (ENSG00000116191), RAPGEF5 (ENSG00000136237), RASGEF1B (ENSG00000138670), RGL1 (ENSG00000143344), RASGEF1C (ENSG00000146090), RASGRP3 (ENSG00000152689), RAPGEF6 (ENSG00000158987), RGL4 (ENSG00000159496), RALGDS (ENSG00000160271), RASGRP4 (ENSG00000171777), RASGRP1 (ENSG00000172575), RASGEF1A (ENSG00000198915), RGL3 (ENSG00000205517), RGL2 (ENSG00000237441)

Protein

Protein identifiers

Ras-specific guanine nucleotide-releasing factor RalGPS1 — Q5JS13 (reviewed: Q5JS13)

Alternative names: Ral GEF with PH domain and SH3-binding motif 1, Ral guanine nucleotide exchange factor 2, RalA exchange factor RalGPS1

All UniProt accessions (3): Q5JS13, H0Y6A2, Q5JT61

UniProt curated annotations — full annotation on UniProt →

Function. Guanine nucleotide exchange factor (GEF) for the small GTPase RALA. May be involved in cytoskeletal organization. Guanine nucleotide exchange factor for.

Subunit / interactions. Interacts with the SH3 domains of GRB2, NCK1, PLCG1 and SRC.

Subcellular location. Cytoplasm. Cell membrane.

Tissue specificity. Widely expressed (at protein level). Isoform 2 is expressed in brain, colon, kidney, pancreas, prostate, skeletal muscle, small intestine, testis, thymus and uterus. Isoform 1 is expressed at high levels in heart and testis and at lower levels in brain, pancreas, skeletal muscle, small intestine and thymus.

Domain organisation. The PH domain mediates binding to membranes. It is required for efficient GEF activity.

Isoforms (7)

UniProt ID	Names	Canonical?
Q5JS13-1	1, RALGPS1B	yes
Q5JS13-2	2, RALGPS1A
Q5JS13-3	3
Q5JS13-4	4
Q5JS13-5	5
Q5JS13-6	6
Q5JS13-7	7

RefSeq proteins (13): NP_001177657, NP_001177658, NP_001177659, NP_001309249, NP_001309250, NP_001309251, NP_001309252, NP_001309253, NP_001309254, NP_001353328, NP_001353329, NP_001353330, NP_055451* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001849	PH_domain	Domain
IPR001895	RASGEF_cat_dom	Domain
IPR008937	Ras-like_GEF	Family
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR023578	Ras_GEF_dom_sf	Homologous_superfamily
IPR036964	RASGEF_cat_dom_sf	Homologous_superfamily

Pfam: PF00169, PF00617

UniProt features (43 total): helix 16, splice variant 11, sequence conflict 3, region of interest 3, domain 2, compositionally biased region 2, chain 1, sequence variant 1, mutagenesis site 1, turn 1, strand 1, short sequence motif 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3QXL	X-RAY DIFFRACTION	2.24

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5JS13-F1	75.96	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
148	loss of activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 168 (showing top): BROWNE_HCMV_INFECTION_30MIN_DN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, CACCAGC_MIR138, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, MODULE_66, BLALOCK_ALZHEIMERS_DISEASE_UP, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GCM_NF2, GGTGAAG_MIR412, MODULE_11, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, TGCCTTA_MIR124A

GO Biological Process (4): Ras protein signal transduction (GO:0007265), regulation of Ral protein signal transduction (GO:0032485), intracellular signal transduction (GO:0035556), small GTPase-mediated signal transduction (GO:0007264)

GO Molecular Function (2): guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	2
cellular anatomical structure	2
small GTPase-mediated signal transduction	1
Ral protein signal transduction	1
regulation of small GTPase mediated signal transduction	1
signal transduction	1
intracellular signaling cassette	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
binding	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1382 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RALGPS1	NUTM2G	Q5VZR2	594
RALGPS1	GARNL3	Q5VVW2	548
RALGPS1	RALB	P11234	510
RALGPS1	RALA	P11233	508
RALGPS1	RALGAPB	Q86X10	508
RALGPS1	RTL9	Q8NET4	486
RALGPS1	DPM2	O94777	475
RALGPS1	NUGGC	Q68CJ6	450
RALGPS1	MAP7D2	Q96T17	427
RALGPS1	UQCC6	Q69YU5	425
RALGPS1	RALGAPA1	Q6GYQ0	417
RALGPS1	REPS2	Q8NFH8	403
RALGPS1	VPS50	Q96JG6	380
RALGPS1	GASK1B	Q6UWH4	361
RALGPS1	SPNS3	Q6ZMD2	360
RALGPS1	ZNF395	Q9H8N7	360

IntAct

4 interactions, top by confidence:

A	B	Type	Score
Dlg4	RALGPS1	psi-mi:“MI:0407”(direct interaction)	0.440
C2orf88	RALGPS1	psi-mi:“MI:0915”(physical association)	0.370
RHOG	COPE	psi-mi:“MI:0914”(association)	0.350

BioGRID (15): RALGPS1 (Affinity Capture-RNA), RALGPS1 (Positive Genetic), RALGPS1 (Synthetic Lethality), RALGPS1 (Two-hybrid), RALA (Biochemical Activity), GRB2 (Affinity Capture-Western), NCK1 (Affinity Capture-Western), RALGPS1 (Affinity Capture-RNA), RALGPS1 (Cross-Linking-MS (XL-MS)), RALGPS1 (Co-fractionation), RALGPS1 (Co-fractionation), RALGPS1 (Reconstituted Complex), RALGPS1 (Affinity Capture-RNA), APP (Reconstituted Complex), RALGPS1 (Two-hybrid)

ESM2 similar proteins: A2AR50, B0UXH6, D3ZAZ5, D4AB98, F1M386, F1MSG6, F1PBJ0, F7EL49, O60343, O75044, O97790, P0CE43, P42331, Q00IB7, Q13905, Q14155, Q15678, Q28CB1, Q4R7W3, Q58DL5, Q5JS13, Q5U2Z7, Q5ZJK0, Q60695, Q60949, Q62130, Q62136, Q6INE5, Q6INP9, Q6P112, Q6P549, Q7Z6B7, Q80TI1, Q86TI0, Q86X27, Q8BYJ6, Q8BYW1, Q8C4V1, Q8CHG7, Q8IV61

Diamond homologs: A2AR50, A2CEA7, B0M0P8, B0UXH6, F1M386, F1MSG6, F1PBJ0, O14827, P27671, P28818, P70392, Q03385, Q03386, Q07889, Q07890, Q12967, Q13905, Q13972, Q3MIN7, Q3UYI5, Q4R7W3, Q54FF3, Q54PQ4, Q54TK8, Q552M5, Q55GH9, Q5JS13, Q5ZJK0, Q60695, Q86G47, Q86X27, Q8CHG7, Q8IS14, Q8IS15, Q8IS16, Q8IS18, Q8IS20, Q8IS21, Q8SSQ0, Q8SSW7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
IRX1	“up-regulates quantity by expression”	RALGPS1	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

6291 predictions. Top by Δscore:

Variant	Effect	Δscore
9:126952903:G:GT	donor_gain	1.0000
9:126952960:G:GT	donor_gain	1.0000
9:126965842:AG:A	acceptor_gain	1.0000
9:126965843:GG:G	acceptor_gain	1.0000
9:126965843:GGGC:G	acceptor_gain	1.0000
9:126965843:GGGCA:G	acceptor_gain	1.0000
9:126965948:TGCT:T	donor_gain	1.0000
9:126965948:TGCTG:T	donor_loss	1.0000
9:126965949:GCT:G	donor_gain	1.0000
9:126965949:GCTG:G	donor_gain	1.0000
9:126965950:CT:C	donor_gain	1.0000
9:126965950:CTGT:C	donor_loss	1.0000
9:126965951:TGTAA:T	donor_loss	1.0000
9:126965952:G:GG	donor_gain	1.0000
9:126965952:GT:G	donor_loss	1.0000
9:126965953:TAAGT:T	donor_loss	1.0000
9:127052935:GGGCT:G	donor_gain	1.0000
9:127052936:GGCT:G	donor_gain	1.0000
9:127052936:GGCTG:G	donor_gain	1.0000
9:127052937:GCT:G	donor_gain	1.0000
9:127052937:GCTG:G	donor_gain	1.0000
9:127052940:G:GG	donor_gain	1.0000
9:127069223:A:AG	acceptor_gain	1.0000
9:127069226:CTA:C	acceptor_loss	1.0000
9:127069227:TA:T	acceptor_loss	1.0000
9:127069228:A:AG	acceptor_gain	1.0000
9:127069228:AGCT:A	acceptor_loss	1.0000
9:127069229:G:GA	acceptor_gain	1.0000
9:127069229:GC:G	acceptor_gain	1.0000
9:127069229:GCT:G	acceptor_gain	1.0000

AlphaMissense

3656 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:126965950:C:A	A55D	1.000
9:126977705:C:A	T59K	1.000
9:126977735:T:A	I69N	1.000
9:127034435:T:C	L74P	1.000
9:127034449:T:A	W79R	1.000
9:127034449:T:C	W79R	1.000
9:127034451:G:C	W79C	1.000
9:127034451:G:T	W79C	1.000
9:127034506:T:C	F98L	1.000
9:127034508:T:A	F98L	1.000
9:127034508:T:G	F98L	1.000
9:127034511:C:A	N99K	1.000
9:127034511:C:G	N99K	1.000
9:127050052:T:A	W104R	1.000
9:127050052:T:C	W104R	1.000
9:127050071:T:A	L110Q	1.000
9:127050071:T:C	L110P	1.000
9:127050094:A:G	R118G	1.000
9:127050094:A:T	R118W	1.000
9:127050095:G:C	R118T	1.000
9:127050095:G:T	R118M	1.000
9:127050096:G:C	R118S	1.000
9:127050096:G:T	R118S	1.000
9:127050097:G:C	A119P	1.000
9:127050107:T:C	L122P	1.000
9:127050128:C:A	A129D	1.000
9:127052851:T:C	L132P	1.000
9:127052867:C:A	N137K	1.000
9:127052867:C:G	N137K	1.000
9:127052896:C:A	A147E	1.000

dbSNP variants (sampled 300 via entrez): RS1000015196 (9:127189256 C>T), RS1000026958 (9:127051755 C>G), RS1000030645 (9:126941300 A>G), RS1000045052 (9:127052025 T>C), RS1000049814 (9:127090893 G>A), RS1000054131 (9:127097175 T>G), RS1000060252 (9:127059533 T>C,G), RS1000063748 (9:126913304 G>A), RS1000078808 (9:126918827 C>A,T), RS1000081401 (9:127173579 C>T), RS1000087395 (9:127003306 T>G), RS1000105970 (9:127087935 A>C), RS1000123215 (9:127103644 G>C), RS1000123747 (9:127132268 T>C), RS1000124582 (9:127064438 T>C)

Disease associations

OMIM: gene MIM:614444 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST003264_163	Post bronchodilator FEV1/FVC ratio	3.000000e-06
GCST005580_229	Intraocular pressure	1.000000e-17
GCST005580_246	Intraocular pressure	9.000000e-11
GCST006412_109	Intraocular pressure	2.000000e-18
GCST007201_109	Schizophrenia	1.000000e-07
GCST007294_106	Body fat distribution (trunk fat ratio)	2.000000e-08
GCST007294_69	Body fat distribution (trunk fat ratio)	1.000000e-09
GCST007295_19	Body fat distribution (leg fat ratio)	1.000000e-09
GCST007295_78	Body fat distribution (leg fat ratio)	3.000000e-13
GCST009066_19	Mosaic loss of chromosome Y (Y chromosome dosage)	1.000000e-12
GCST009725_26	Intraocular pressure	2.000000e-14
GCST010703_39	Brain morphology (MOSTest)	9.000000e-09
GCST012368_6	Early-onset schizophrenia	4.000000e-11
GCST90000025_381	Appendicular lean mass	1.000000e-17

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004713	FEV/FVC ratio
EFO:0004695	intraocular pressure measurement
EFO:0004341	body fat distribution
EFO:0007783	mosaic loss of chromosome Y measurement
EFO:0004346	neuroimaging measurement
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	5
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	4
trichostatin A	increases expression, affects cotreatment, decreases expression	3
Aflatoxin B1	affects expression, decreases expression, increases methylation	3
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
Smoke	increases expression, decreases expression, increases abundance	2
Cyclosporine	decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
beta-lapachone	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
periodate-oxidized adenosine	affects expression	1
aflatoxin B2	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases methylation	1
jinfukang	affects cotreatment, decreases expression, increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases expression, increases abundance	1
Arsenicals	increases methylation	1
Caffeine	decreases phosphorylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.